The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
BNB continues to demonstrate relative strength within broader market conditions, with price action maintaining a stable higher-timeframe structure despite recent retracement phases.
Market behavior reflects measured participation, controlled volatility, and technical positioning that favors structural preservation rather than disorderly decline.
Participants appear to be monitoring confirmation zones rather than initiating high-leverage exposure, keeping the coin within a controlled consolidation channel.
BNB trades at $915 as the market enters a neutral consolidation phase, while open interest data highlights a lack of strong leveraged positioning.
The one-hour BNB/USD chart shows the price recovering from a short-term dip to $885, then gradually climbing into the current range.
However, aggregated open interest has been grinding lower between $863M and $860M, signaling reduced speculative positioning and a preference for passive exposure instead of directional leverage buildup.
Source: BNB Open Interest data
The absence of forced liquidations or sharp spikes reflects controlled positioning, which may help reduce volatility risk if the price continues to stabilise above $900.
Current derivatives behaviour implies that the BNB Price Prediction outlook remains dependent on renewed conviction rather than short-term speculative swings as the market tests whether buyers can reclaim initiative in the coming sessions.
Publicly available market statistics position BNB at approximately $928.74, recording a 0.58% increase over the past 24 hours.
Market capitalization stands near $125,018,531,846.00, supported by $3,329,292,453.00 in trading volume, while the current circulating supply reflects 137,736,891 coins. Data positioning confirms the coin remains within the upper-tier capitalization bracket, holding its status inside the global top five
Recent trading behavior shows price fluctuating inside a $928.74 intraday channel, aligning with stable liquidity readings rather than high-volatility displacement.
Volume activity shows consistent but non-expansive engagement, indicating balanced participant presence. The neutral profile does not reflect either forced selling pressure or early breakout accumulation patterns typically seen at trend inflection points.
Funding, VWAP Behaviour and Sentiment Indecision
CoinGlass data shows visible oscillations in volume-weighted behavior relative to price movement, with a clear divergence emerging during the most recent trend shift.
While the coin showed upward progression earlier, funding sentiment and VWAP indications moved in alternating bands, revealing short-lived phases of dominance from both sides of the market.

Source: Coinglass analytics
The price-to-volume relationship also reflects a transition from momentum continuation to range equilibrium conditions.
Based on current derivatives rhythm and order-flow cooling, BNB Price Prediction modelling favours neutrality until stronger conviction returns, potentially aligning with rising volume and break-level confirmation.
TradingView’s daily analysis shows BNB holding the lower Bollinger Band near $859, while the price remains below the middle band resistance at $979.
The Bollinger structure reflects a completed volatility expansion cycle turning into controlled compression. MACD remains in negative territory with the histogram showing a gradual reduction in selling momentum, suggesting deceleration rather than trend continuation.

Source: TradingView BNB chart
The price range between $885 and $920 forms a near-term accumulation zone, and sustained closes above $950 would represent the first technical confirmation of a short-term shift.
Technical structure remains consistent with a measured correction cycle, making the BNB Price Prediction outlook dependent on price reclaiming mid-range levels with directional volume support.
The near-term weather is the anchor dragging us down. The NatGasWeather outlook for the rest of the week through next weekend shows a quick cool blast in the Northeast fading fast. Most of the country is warming up, running highs from the 40s all the way to 80s down south. This means demand goes from “Moderate” to “Low” real quick. It’s a classic wait-and-see move as players sit on their hands until the next legitimate cold snap shows up.
The fundamental story keeping a lid on any rally is production. The Lower-48 states are pumping out a massive 110.0 bcf/day, which is a solid 7.1% jump year-over-year (y/y). The EIA sees no let-up, hiking its 2025 production forecast to 107.67 bcf/day. We also whiffed on last Friday’s storage report, posting an inventory build of +45 bcf—way over the +34 bcf whisper. This leaves stockpiles sitting +4.5% above the 5-year average. Too much supply on the screen, period.
It’s not all doom and gloom, though. The downside is limited by relentless export demand. LNG flows are still running hot at around 17.6 bcf/day. More importantly, power demand is creeping higher; last week saw Lower 48 power producers consume 6.1% more gas. We’ve got earnings coming up from Helmerich & Payne and Nvidia this week, which will give us a read on drilling activity and the future pull from massive data center construction. This structural demand boom is what keeps the longer-term bulls in the game.
The immediate focus is the EIA print for the week ended November 14. Analysts are calling for the first real drawdown of the season—a 17 Bcf withdrawal. That’s a massive shift from the 5-year average injection of 12 Bcf. This signals that heating demand, driven by a 24-week/week jump in Lower 48 heating degree days, is finally kicking in. This flip to a withdrawal could be the catalyst that triggers the bottom for this pullback.
Who are the safest tea brands without PFAS “forever chemicals?” This is the question that Mamavation has been attempting to answer for you by sending the most popular tea brands to our EPA-certified laboratory to test. After all that testing, which tea brands and tea products do we recommend? You’ve trusted Mamavation to bring you topics like (1) safest cooking oils tested for phthalates, (2) safest coffees tested for pesticides, PFAS “forever chemicals,” and mycotoxins, and (3) safest protein powders tested for pesticides, PFAS “forever chemicals”, phthalates, and heavy metals, now join us for the safest teas without PFAS “forever chemicals.”
Disclosure: This consumer study is released in partnership with Environmental Health News. Donations were provided by Environmental Health News and Mamavation community members. Note that Mamavation has only “spot-checked” the industry and thus we cannot make predictions about brands and products that we have not tested. Products and manufacturing aides can change without notice so buyer beware. This post contains affiliate links, with some to Amazon, which means Mamavation will receive a portion of those sales and we will use that to pay ourselves back for the testing. You can also give a tax-deductible donation to our consumer studies here through Environmental Health Sciences. Thank you!

Mamavation has been testing several categories of teas for specific PFAS “forever chemicals,” and we thought it would be useful to bring you a synopsis of what was found thus far all together in one place. Note that some teas tested higher for PFAS compounds than others. The PFAS levels that were high enough to quantify are referred to as “quantifiable PFAS” and you’ll find all those results at the bottom of this post.
Here’s a quick synopsis of how much PFAS was found in each category:


PFAS “forever chemicals” are problematic for human health and the environment. They are considered ubiquitous, persistent, and toxic. Therefore, reducing the amount of PFAS you are exposed to from food, water, and other beverages like tea is imperative. Mamavation is dedicated to helping you do that when shopping for tea.
Here are some of the adverse health effects of different PFAS “forever chemicals:”
It’s also very clear, based on biomonitoring evidence from the Centers for Disease Control & Prevention (CDC), that PFAS are in all Americans. Therefore, these exposures can harm most Americans.


The past five years have seen a flurry of studies looking at specific PFAS compounds and certain foods and beverages like tea. One study claimed that people who drank more tea were more likely to have higher levels of PFAS in their blood. Here are some recent examples of studies done on teas:
Terrence Collins, Teresa Heinz Professor of Green Chemistry & Director of the Institute for Green Sciences at Carnegie Mellon University had this to say about the study: “This study looks at an important question for green tea drinkers. Are ‘forever chemicals’, PFAS compounds that the human body cannot break down and tends to hold on to, in the product contaminant profile? The results speak for themselves. No one wants to be ingesting PFAS when they drink green tea! It’s somewhat comforting that PFAS contamination is not universal, at least in Mamavation’s spot-testing. Green tea drinkers are now armed with the knowledge to send messages of approval or disapproval through their buying habits across the green tea business world.”


Earl Grey Teas, Chamomile Teas, and Green Teas were purchased in 2024 and 2025. Each product was recorded in our database and sent directly to the lab within its original packaging.
Testing Loose Leaf Tea: Mamavation’s EPA-certified laboratory used method EPA 1633 to test for 40 PFAS compounds, including the following:


Our lab found quantifiable amounts of specific PFAS within these tea leaves. Of the 40 PFAS analytes tested for at least one was found. We also put brands here where we found over 200 ppm of total fluorine in the tea sachets.
These products were sent off to an EPA-certified laboratory. The tea leaves were tested for 40 PFAS analytes and each product had positive results. The tea bags were tested for fluorine, a marker of PFAS “forever chemicals.”
These products were sent off to an EPA-certified laboratory. The tea leaves were tested for 40 PFAS analytes, and each product had positive results.


Our lab could not find quantifiable amounts of specific PFAS compounds; however, they did find the presence of at least one specific PFAS compound within the tea leaves. This means the lab could detect PFAS, but it wasn’t in high enough amounts to determine how much was in there. If tea bags were available, our lab also tested those bags separately for total fluorine, which is an indicator of PFAS and fluoride combined.
These products were sent off to an EPA-certified laboratory. The tea leaves were tested for 40 PFAS analytes and each product had positive results, however, the results were so small they were not quantifiable. The tea bags were tested for fluorine, a marker of PFAS “forever chemicals.” We also included one brand that did not have detectable PFAS, but had detectable fluorine in their tea bags.
These products were sent off to an EPA-certified laboratory. The tea leaves were tested for 40 PFAS analytes and each product had positive results, however, the results were so small they were not quantifiable.


Our lab determined no PFAS compounds were found in the Earl Grey tea leaves. However, the tea bags had detectable fluorine.
These products were sent off to an EPA-certified laboratory. The tea leaves were tested for 40 PFAS analytes and each product had non-detect results. The tea bags were tested for fluorine, a marker of PFAS “forever chemicals,” and also had non-detect results.
These products were sent off to an EPA-certified laboratory. The tea leaves were tested for 40 PFAS analytes and each product had non-detect results.
Jessie A Ellis
Nov 18, 2025 09:29
MATIC price prediction shows potential for recovery to $0.50 within 4-6 weeks as technical indicators suggest oversold conditions, though immediate weakness persists below key resistance.
Polygon (MATIC) finds itself at a critical juncture as November 2025 trading continues, with the token hovering near multi-month lows at $0.38. Our comprehensive MATIC price prediction analysis reveals a complex technical picture that suggests potential for significant upside movement despite current bearish momentum indicators.
• MATIC short-term target (1 week): $0.42 (+10.5%) – testing SMA 20 resistance
• Polygon medium-term forecast (1 month): $0.48-$0.55 range – 26-45% upside potential
• Key level to break for bullish continuation: $0.43 (SMA 20 resistance)
• Critical support if bearish: $0.33 (strong support level)
The latest Polygon forecast from multiple analytical sources presents a notably divergent picture. Recent MATIC price prediction models show targets ranging from conservative $0.165 estimates to extremely bullish $7.692 projections for medium-term timeframes.
Changelly’s near-term MATIC price target of $0.165 appears overly pessimistic given current support levels, while LongForecast’s $7.692 projection seems unrealistic without fundamental catalysts. The most credible predictions center around PricePredictions.com’s $0.732773 target and CoinGape’s $0.255771 forecast, both suggesting meaningful upside from current levels.
CoinArbitrageBot’s AI-driven $0.23048 short-term target aligns more closely with current technical resistance levels, though our analysis suggests higher probability for the $0.42-$0.50 range based on historical support and resistance patterns.
Current Polygon technical analysis reveals MATIC trading significantly below all major moving averages, with the token sitting 45% below its SMA 200 at $0.69. However, several indicators suggest oversold conditions that often precede meaningful reversals.
The RSI reading of 38.00 positions MATIC in neutral territory but approaching oversold levels, while the Bollinger Bands show price action in the lower 29% of the bands – historically a zone where bounces occur. The daily ATR of $0.03 indicates relatively low volatility, suggesting potential for increased movement as consolidation ends.
MACD momentum remains bearish with a -0.0045 histogram reading, but the narrow spread between MACD (-0.0246) and signal line (-0.0202) suggests weakening selling pressure. Stochastic indicators show %K at 25.19, approaching oversold territory that typically generates buying interest.
Volume analysis reveals relatively light trading at $1.07 million on Binance spot, indicating limited conviction in current price levels and potential for significant moves on increased participation.
The primary bullish MATIC price target focuses on a recovery to $0.50-$0.55, representing 30-45% upside from current levels. This projection relies on several technical factors aligning:
First, MATIC must reclaim the SMA 20 at $0.43, which would signal the beginning of short-term trend reversal. Success above this level opens the path to test the upper Bollinger Band at $0.56, closely aligned with strong resistance at $0.58.
Our most confident MATIC price prediction sees initial resistance at $0.43 giving way to momentum-driven moves toward $0.48-$0.50 within 4-6 weeks. This scenario requires RSI to break above 50 and MACD to generate a bullish crossover above the signal line.
The ultimate bullish target sits at $0.58, representing the confluence of multiple resistance levels and offering 52% upside potential. However, this level would require significant fundamental catalysts or broader market recovery to achieve.
Downside risks for this Polygon forecast center on a breakdown below current support at $0.35, which could trigger stops and accelerate selling toward the strong support zone at $0.33. This level represents the 52-week low vicinity and would likely generate defensive buying.
A break below $0.33 would invalidate our bullish MATIC price prediction and potentially target the psychologically important $0.30 level. Such a scenario would require broader cryptocurrency market weakness or Polygon-specific negative developments.
The most concerning technical development would be RSI falling below 30 combined with increased selling volume, which could trigger a deeper correction toward $0.28-$0.30 levels.
Current levels present a compelling buy or sell MATIC decision point for medium-term traders. Our recommendation favors accumulation strategies given the oversold technical conditions and proximity to strong support levels.
Optimal entry points for MATIC purchases include current levels around $0.38 with additional buying at $0.35 if weakness persists. This dollar-cost averaging approach capitalizes on potential volatility while managing downside risk.
Risk management requires strict stop-loss placement below $0.32, representing approximately 16% maximum loss from current entry levels. Position sizing should remain conservative given the uncertain broader market environment, with recommendations for 1-2% portfolio allocation maximum.
For aggressive traders, call options targeting the $0.50 strike price with 6-8 week expiration may offer leveraged exposure to potential upside moves, though these positions require careful risk management.
Our comprehensive analysis generates a medium confidence MATIC price prediction targeting $0.50 within 4-6 weeks, representing approximately 30% upside from current levels. This forecast relies on successful defense of the $0.35 support level and subsequent reclaim of $0.43 resistance.
Key technical indicators to monitor for prediction confirmation include RSI breaking above 45, MACD generating a bullish crossover, and volume expansion above 1.5 million daily average. Invalidation signals include breaks below $0.33 support with confirmed selling volume.
The timeline for this Polygon forecast extends through December 2025, with intermediate checkpoints at $0.42 (1-2 weeks) and $0.46 (3-4 weeks) serving as confidence builders for the ultimate $0.50 target. Traders should remain flexible and adjust positions based on evolving technical conditions and broader market sentiment.
Image source: Shutterstock
Tal como se relató a Erica Rimlinger
Solía asistir a celebraciones navideñas todos los años tostada y brillando con un bronceado nuevo. Broncearme era parte de mi rutina regular de belleza y me sentía incompleta si no lo hacía. Nunca pensé que cancelaría mi membresía en el salón de bronceado al que fui durante mucho tiempo, pero ese día llegó.
El formulario de cancelación solicitaba un motivo. Escribí con letras grandes: MELANOMA. Tenía 26 años, me habían diagnosticado recientemente una de las formas más mortales de cáncer de la piel y estaba furiosa conmigo por ignorar las advertencias en letras pequeñas del contrato. El empleado del salón miró mi formulario después de que lo contesté, dijo, “está bien, ya acabaste” y se fue.
Días antes, mi mamá me rogó que haga que examinen un lunar en mi pecho. Estaba preocupada porque a mi papá le diagnosticaron melanoma de etapa 0 el mes anterior. Pensé que el diagnóstico de mi papá le estaba dando paranoia. Solo cinco semanas después de cumplir 26 años, era mucho más joven que mi papá y mi lunar sospechoso se veía como el de él. El mío no era grande como el lunar de mi papá, pero tenía varios colores con bordes irregulares.
Ignoré a mi mamá diciendo “seguro, mamá”, pero su preocupación se fijó en mi cerebro. Usé Google para investigar y vi muchas fotos de lunares sospechosos. Finalmente pensé, está bien, no pierdo nada si hago que un dermatólogo examine mi piel.
Estaba poco preparada para la experiencia de pararme desnuda, de cabeza a pies, frente a un doctor que conocí apenas cinco segundos antes. Tengo muchos lunares y a medida que el doctor los inspeccionaba, me preguntaba sobre mi uso de camas de bronceado, mis antecedentes familiares de melanoma y mis hábitos en lo que se refiere al sol. Empecé a sentirme incómoda y me puse un poco a la defensiva. Vivo en Ohio donde no recibimos mucho sol y broncearse es un estándar de belleza. No ves a modelos que no estén bronceadas, ¿verdad? El doctor me preguntó si tenía algún lunar que me preocupase. Obstinadamente, dije no.
2019
Sin embargo, se acercó a ver el que le preocupó a mi mamá. No se veía como mis otros lunares. Lo extrajo para una biopsia y pensé, “maravilloso. Ya acabamos”. Había escuchado de personas a quienes les removían lunares precancerosos todo el tiempo. Eso no significaba que ocurría algo malo. Mi mamá estaría feliz de que hayan examinado mi piel y debo admitir que yo también me sentía un poco mejor.
El doctor dijo que tendría los resultados en tres a cinco días laborales, pero pasaron 10 días y no me dijo nada. Llamé al consultorio y pregunté si perdieron mi lunar. El equipo médico pidió disculpas y dijo que lo enviaron para pruebas adicionales. Ahí es cuando sentí la primera sensación negativa.
En el 14º día después de la biopsia, estaba en el auto con mi esposo cuando el consultorio del dermatólogo llamó con mis resultados. El tono sombrío de la voz de mi doctor anunció el melanoma antes de decirlo con palabras. Afortunadamente mi esposo estaba manejando. Tenía melanoma de etapa 1a que estaba a punto de convertirse en etapa 1b. Lo primero que pensé fue, “esto es peor que el caso de mi papá”. Luego pensé, “¿cómo podía ser peor que el de mi papá?”. El doctor recomendó una cirugía inmediata y una prueba de los ganglios linfáticos. Toda la llamada duró menos de 10 minutos, pero mi rostro estaba pálido y mi mundo también perdió su color.
Dos semanas después de esa llamada telefónica, fui al hospital por ocho horas. Nunca antes me habían anestesiado. El único procedimiento médico que había tenido hasta entonces era la remoción de mis muelas del juicio. Desperté después de la cirugía con dos incisiones grandes y mucha pena por la vida que ya no tenía. Me encantaba broncearme. Y eso estaba arraigado profundamente en mi imagen corporal. Además de la pena, también estaba enojada conmigo, con el sol e incluso con el hábito de mi papá de quemarse cuando cortaba el césped o cuando jugaba golf.
Quería correr, levantar pesas y acostarme bajo el sol nuevamente. Los primeros dos deseos tendrían que esperar hasta que sane y el tercero ya no era una opción para mí. Debía cambiar mi estilo de vida y cancelar mi membresía al salón de bronceado.
Deje de tener pena por eso después de un mes y medio. Comprendí que eso no servía de nada y que tenía la oportunidad de aprender, cambiar mis hábitos y dar gracias por mi segunda oportunidad. Pero hacía esto en silencio, sin decirlo casi a nadie debido a la vergüenza que sentía por mi diagnóstico.
2024
Durante los dos siguientes años después de mi cirugía, me sometí frecuentemente a evaluaciones de mi piel y perdí la cuenta de las biopsias que tuve. Sentía como si estuviesen rebanando mi cuerpo. El peso de la carga mental, emocional y física de sobrevivir, hizo que comprenda que necesitaba apoyo. Era hora de compartir mi historia.
En las redes sociales, encontré #melanoma y me sorprendió cuantas personas que tenían un poco más de 20 años compartían historias de sus melanomas. Tomé una foto de mis cicatrices, la publiqué, entré en pánico y lancé el teléfono al otro lado del cuarto.
La mofa, vergüenza y mensajes de “te lo dije” que esperaba nunca aparecieron, ni siquiera una vez. En vez de eso, mi comunidad me dio amor y apoyo y yo estaba muy agradecida. Una vez que empecé a interactuar con otros sobrevivientes de melanoma y consejeros, mi carga se desvaneció.
Me alegra haber buscado apoyo cuando lo hice. El melanoma de mi papá reapareció en su cerebro y pulmones. Después de 21 rondas de inmunoterapia, radiación de bisturí de rayos y y varios viajes a la sala de emergencias, las lesiones de mi papá empezaron a encogerse. Actualmente, mi papá todavía está aquí y su melanoma ha desaparecido casi por completo. Estamos tan agradecidos y esta experiencia ha hecho que nuestra familia esté mucho más unida.
Leah y su padre en su matrimonio, junio de 2025. (Foto/Aisley Herndon
Ahora acepto el hecho de haber amado el sol. En vez de culparme en silencio, digo lo que siento y concientizo a otras personas para que se cuiden del sol y para que se sometan a examinaciones de la piel. Soy voluntaria en la Melanoma Research Foundation [Fundación de investigación del melanoma] y estoy en el comité de líderes de la Melanoma Research Alliance [Alianza de investigación del melanoma] (MRA). En lo que se refiere a la MRA, voy al capitolio cada año, a pedirle al congreso que proteja el financiamiento de investigaciones, que prohíba las camas de bronceado y que investigue de mejor forma los ingredientes de los protectores solares.
En vez de torturarme por no protegerme del sol cuando era adolescente y adulta joven, estoy trabajando para cambiar la cultura que motiva a las personas a que ignoren los riesgos de broncearse. Todavía asisto a las fiestas navideñas brillando, pero ahora con gratitud y no por haberme bronceado.
Este recurso educativo se preparó con el apoyo de Merck.
¿Eres una mujer con historias reales que te gustaría compartir? Avísanos
Nuestras historias son experiencias auténticas de mujeres reales. HealthyWomen no avala los puntos de vista, opiniones y experiencias expresados en estas historias y no reflejan necesariamente las políticas o posiciones oficiales de HealthyWomen.
From Your Site Articles
Related Articles Around the Web
Spot Gold hovers around $4,060 in the American session on Tuesday, easing from an intraday peak of $4,082. The XAU/USD pair is little changed for a second consecutive day, reflecting investors’ wait-and-see stance ahead of United States (US) data releases scheduled for later this week.
Following the US federal shutdown, the government was finally able to pass a funding bill last week, which means governmental offices resumed activity and hence, data collection.
Market participants are cautious ahead of the announcement, but also wary about earnings reports. Among other companies, Home Depot reported weakening sales growth and cut its outlook for the financial year, blaming the downturn in its performance on a sluggish housing market and weaker consumer sentiment.NVIDIA is also scheduled to report this week, and the results could disrupt financial markets, especially tech-related reports.
Other than that, the US published August Factory Orders, which were up 1.4% on a monthly basis, improving from the -1.3% posted in July. The data is old, but it helped maintain the US Dollar (USD) afloat ahead of more relevant macroeconomic figures.
Additionally, ADP released the four-week average on Employment Change, which showed US private employers shed an average of 2,500 jobs a week in the four weeks ending November 1.
From a technical point of view, the 4-hour chart shows XAU/USD trading at $4,067.90, up for the day. The 20-period Simple Moving Average (SMA) has turned lower, providing dynamic resistance at around $4,090. At the same time, the 200-period SMA continues to rise modestly, now standing at $4,074.85, while holding above the 100-period at $4,041.52, the latter providing relevant dynamic support. Meanwhile, the Momentum indicator remains below its midline but edges higher, indicating waning bearish pressure. Finally, the Relative Strength Index (RSI) stands neutral at 46.
In the daily chart, XAU/USD has posted a lower high and a lower low, hinting at increased selling interest without confirming an upcoming decline. The 20-day SMA has turned lower, while the 100- and 200-day SMAs continue to rise, keeping the broader trend supported. Price holds above all these averages, suggesting buyers retain the upper hand. Technical indicators hold within positive levels, with the Momentum rising above its midline, and the RSI holding neutral around 52 with scope to extend if bulls press the advantage. The pair needs to recover beyond the $4,100 level to become more attractive to bulls, an unlikely scenario at the time being.
(The technical analysis of this story was written with the help of an AI tool)
While matcha green tea is often hailed as a trendy superfood with numerous health benefits, it can actually be significantly harmful for some people, as one woman discovered when she found herself in hospital. Laura Mae shared her experience on TikTok from her hospital bed, where she was being treated for iron deficiency.
In a video that has since gone viral, amassing more than 10 million views, she attributed her ill health to her daily consumption of matcha. “When you realise the matcha you have been drinking every morning is likely the reason your hair is falling out,” she captioned the video.
Laura Mae went on to explain: “Matcha can block your body’s natural iron absorption, which can increase hair loss, brittle nails, and fatigue.”
In a subsequent video, she revealed that she used to attribute all her health issues to her Crohn’s Disease. However, once she considered her regular intake of matcha, everything started to make sense, reports the Mirror.
“Once I realised my daily matcha was making iron absorption even harder, it all clicked,” said Laura Mae. “Swapping my morning drink was the best change I’ve made.”
She added: “Gut health really is everything. Once I changed my morning routine, the symptoms finally started to make sense.”
Following her discharge from hospital, Laura Mae shared with her followers: “Not every ‘healthy habit’ is healthy for everybody. For me, matcha was secretly making things worse, especially with absorption already being a struggle.
“Once I swapped it out, I noticed the difference in my energy and mood almost immediately. I didn’t realise how much my daily matcha was holding me back until I swapped it for something my body actually thanked me for.”
Supporting Laura’s worries, Verywell Health cautions that matcha contains tannins and other compounds which can hinder iron absorption.
“Matcha is a type of powdered green tea well known for its high antioxidant content,” the organisation states online.
“It also contains a unique combination of caffeine and L-theanine, a natural amino acid that has been shown to help with energy, stress, and focus, often making it a gentler alternative to coffee.
“[Tannins are] a type of polyphenol that can bind iron in the digestive tract, making it harder for the body to absorb. Because matcha is much more concentrated than regular green tea, it contains more of these polyphenols that will block your body from absorbing iron.”
Meanwhile, Matcha.com also cautions: “According to research, matcha tea does contain compounds that may limit the absorption of iron in the bloodstream. If you are concerned about your iron levels and at risk of iron anemia, try to avoid drinking your matcha or green tea after or within an hour of an iron-rich meal or iron supplements.
“This is because the main healthful compounds found in matcha tea will bind to iron and cause both to lose their ability to be as readily absorbed.”
XRP’s price is down – but its fundamentals are hotter than ever. Canary’s XRPC ETF launched with a bang last week, attracting $58 million in opening-day volume. The move reflects deep institutional interest – and excitement is growing, with Franklin Templeton’s XRP ETF set to launch today.
Despite ETF tailwinds, the XRP price followed the broader market into bearish territory this week, falling 12% to $2.15 today. However, with institutional appeal clearly there, could we see XRP rebound in the weeks ahead?
Our XRP price prediction aims to evaluate the potential impact these ETFs could have on the asset’s short- and long-term pricing dynamics. We’ll consider both the historical performance of other cryptos with ETFs and analyst opinions.
But as the market focuses on XRP, analysts have spotted another crypto that’s currently flying under the radar – but could offer massive upside. It’s called Maxi Doge (MAXI), and it’s building traction in its presale at an impressive pace, raising $4 million thus far.
This publication is sponsored. CryptoDnes does not endorse and is not responsible for the content, accuracy, quality, advertising, products or other materials on this page.
Canary’s XRPC ETF burst out of the gate with $245 million of creations (new shares of the ETF) on day one. ETF expert Eric Balchunas declared that both XRPC and the newly listed Bitwise Solana ETF BSOL “are in a league of their own,” with no other 2025 ETF launch coming close to their initial momentum, reflecting deep investor appetite for mainstream altcoin exposure.
Congrats to $XRPC for $58m in Day One volume, the most of any ETF launched this year (out of 900), BARELY edging out $BSOL‘s $57m. The two of them are in league of own tho as 3rd place is over $20m away. pic.twitter.com/MjsOeceeNb
— Eric Balchunas (@EricBalchunas) November 13, 2025
The crypto analyst Diana underlined that Franklin Templeton is next in line to launch its XRP ETF today. This will be followed by Bitwise on Thursday, then 21Shares, CoinShares, Grayscale, and WisdomTree – all within the next week.
🚨UPDATE: FRANKLIN TEMPLETON’S XRP ETF (EZRP) GOES LIVE TUESDAY 🚨
…and Bitwise is right behind it on November 20. 😳🔥
Franklin Templeton (@FTI_US) — a $1.5 TRILLION asset manager — is launching its $XRP ETF (EZRP) on the CBOE THIS TUESDAY.
Analysts are already saying EZRP… pic.twitter.com/tMV70zsTQT
— Diana (@InvestWithD) November 16, 2025
Both Bitcoin and Ethereum ETF launches in 2024 demonstrated a similar dynamic to what we’ve seen so far with XRP and Solana: strong institutional demand, but negative immediate price movements. However, the long-term effects of ETF demand helped fuel the BTC and ETH rallies during this market cycle.
It took Bitcoin less than one month after its January 2024 ETF launch to gain bullish momentum, whereas it took Ethereum between 4 months and a year, due to intermittent volatility.
Judging by Canary’s ETF launch, Franklin Templeton and other issuers are likely to drive significant fresh demand into XRP, which could help fuel the next rally – especially if the broader market rebounds. But what are analysts saying?
Steph Is Crypto notes that XRP has a deep liquidation cluster above $3, suggesting that the price could move in this direction next.
However, Crypto Fergani suggests that the rally could extend toward $6. One reason this analysis holds credibility is that unlike other major cryptos such as Bitcoin, Ethereum, and Solana, XRP has successfully defended its key $2 support level despite the crash, providing structural strength that could enable a stronger rebound.
XRP’s combination of institutional appeal, upside liquidity risk, and structural chart strength is an exciting setup. It makes the project one of the standout players in line for an aggressive rebound. But as optimism builds, another project analysts believe is poised for substantial gains is Maxi Doge – so let’s look at what it’s all about.
Maxi Doge (MAXI) is undergoing a presale – and it’s on fire. The project has successfully raised over $4 million so far, fueled by rising investor appetite as projects already listed on exchanges struggle.
It’s branded around Dogecoin’s Shiba Inu motif, but introduces an entirely new concept. Futures trading integrations, community rewards, and degen-themed branding are its three main pillars.
The team plans to integrate MAXI into perpetual futures platforms, allowing users to trade it with leverage in both directions if they wish. There will also be weekly trading competitions, where MAXI holders with the highest trading ROI receive free tokens, adding an interactive, competitive element to the project.

Furthermore, the team plans to run community activation events to boost holder engagement. It has also added a staking mechanism to the presale that provides passive rewards, currently valued at a 76% APY.
With over $4 million raised, it’s clear that a lot of investors have belief in Maxi Doge’s potential. And leading analysts do too: Alessandro De Crypto recently predicted MAXI could see 100x gains, for example.
The past few months have been rough for crypto. Bitcoin has slid 28% from its ATH, and most altcoins have taken even bigger hits. But with institutional capital now flowing into altcoin ETFs, the tide may finally be turning.
If bullish momentum rekindles, XRP hitting $6 in the coming months is a real possibility. Meanwhile, Maxi Doge’s early-stage positioning, fast-growing presale, and innovative meme-utility approach give it the potential to deliver even larger upside.
This publication is sponsored. CryptoDnes does not endorse and is not responsible for the content, accuracy, quality, advertising, products or other materials on this page. Readers should do their own research before taking any action related to cryptocurrencies. CryptoDnes shall not be liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with use of or reliance on any content, goods or services mentioned.
A biosimilar is a medicine that is similar to an existing, brand name biologic medicine (a medicine made from living cells and organisms). Although biosimilars are not identical copies of biologics, they’re very close and work in the same way.
Like biologics, biosimilars have many different uses, including treating certain types of cancer.
We spoke with Gury Doshi, M.D., medical director at Texas Oncology-Houston West and chair of The US Oncology Network Pharmacy and Therapeutics committee, to learn more about these promising treatments.
Biologics are medicines that are made up of living cells or organisms. That’s why they’re called biologics — bio meaning living cells. Some examples of biologics are gene therapies, stem cell therapies, monoclonal antibodies and recombinant proteins.
These medicines are used to treat chronic conditions, including autoimmune disorders like rheumatoid arthritis, lupus and Crohn’s disease, as well as some cancers.
A generic medication is an exact chemical copy of a medicine, with identical active ingredients. It’s not possible to make an exact copy of a biologic since they’re made from a living source, so biosimilars are as close as you can get. There are slight differences between the two, but not enough to affect their structure or function.
Yes, absolutely. The FDA won’t allow a biosimilar on the market unless they see data showing safety and effectiveness. After the medicine has been approved, they continue to keep an eye on it to make sure it’s safe and works the way it should.
The approval process for a biosimilar is an abbreviated process. When the FDA is deciding whether to approve a biosimilar, they don’t look at how chemically close the medicine is to the biologic it’s modeled after. They only look at whether the biosimilar is safe and effective.
The fact that biologics are made from living cells and organisms is what makes them special, but it also makes them a little more expensive to develop. Since biosimilars are based on a biologic as opposed to being invented from scratch, they don’t cost as much to make. This savings often gets passed on to patients.
Having a cheaper but just as effective alternative to biologics means we can offer these treatments to more patients and get them started sooner — which may ultimately lead to better outcomes.
Read: Understanding Biosimilars: Better Access to Advanced Medicines >>
No. Insurance companies now understand the role of biosimilars, and they get that everybody (including insurers) benefits from having more treatment options. In my experience, they’re very comfortable with covering biosimilars, but which biosimilars are covered will vary according to a person’s insurance plan.
Biosimilars have ushered in an era of expanded possibilities for cancer treatment. The type of biosimilar now used the most for cancer treatment is monoclonal antibodies. These medicines work by binding to a certain protein on a cancer cell, helping to block signals for cancer growth.
One is called bevacizumab, and it’s used to treat metastatic colon cancer, lung cancer and kidney cancer. Others we use are trastuzumab to treat HER2-positive breast cancer, and rituximab to treat non-Hodgkin’s lymphoma.
We also use biosimilars to provide supportive care to patients with cancer. One called epoetin helps with anemia caused by chemotherapy, and another called filgrastim is used for neutropenia (low white blood cell counts).
Questions you could ask are:
It’s our job as providers to make sure our patients know they have choices in their treatment and to have all the information they need about these choices.
Biosimilars have opened up cancer treatment opportunities for patients not just in the United States, but throughout the world. They’ve really been the unsung heroes of modern cancer treatment.
This educational resource was created with support from Sandoz.
From Your Site Articles
Related Articles Around the Web
Neha Bhasin was a part of India’s first all-girls pop group Viva. After a Channel V executive made disrespectful comments about her body in a room full of people, the singer attempted suicide by consuming more than half a bottle of fat burners.
Popular female playback singer Neha Bhasin is known for her several hit Bollywood songs including Jag Ghoomeya in Sultan, Kuch Khaas Hai in Fashion, Dhunki in Mere Brother Ki Dulhan, and Chashni in Bharat. Her singing journey began at the age of 18 when she won the singing reality show Channel V’s Coke [V] Popstars in 2002, along with four other young singers – Seema Ramchandani, Pratichee Mohapatra, Mahua Kamat and Anushka Manchanda. They formed India’s first all-girls music group Viva.
In a podcast with comedians Bharti Singh and Haarsh Limbachiyaa earlier this year, Neha recalled that she was put on fat burners a year after becoming a part of Viva. She shared that she was unaware of their effects at such a young age. She also recalled a shocking incident when one of the executives from Channel V made disrespectful comments about her body in a room full of people.
“He paused a music video, circled my stomach on screen, and said ‘See, you are so fat. Because of this, we can’t release the video.’ I was 50 kg at that time. I remember going home and, in anger, consuming more than half a bottle of fat burners. That was my way of trying to commit suicide. For two days, I was throwing up. The band did not know what had happened”, Neha stated.
While everyone knows about her singing career, not many know that Neha Bhasin also tried her hand at acting. She starred in the 2012 black comedy film Life Ki Toh Lag Gayi, that also featured Kay Kay Menon and Ranvir Shorey. The movie received horrible reviews from the audiences and critics, and bombed at the box office. The singer was also a part of the controversial reality shows Bigg Boss OTT Season 1, hosted by Karan Johar, and Bigg Boss 15, hosted by Salman Khan, in 2021.